Abstract
ObjectivesTo evaluate the efficacy of Human Urinary Kallidinogenase (HUK) for secondary stroke prevention in the treatment of acute ischemic stroke (AIS) patients.Materials and MethodsIn this retrospective study, from October 2016 to June 2017, 300 consecutive AIS patients were registered in our database. Among them, 145 patients received HUK treatment (HUK group), and 155 patients received basic treatment (control group). Basic treatment was administrated on all patients. 0.15 PNA unit of HUK injection plus 100 ml saline in intravenous infusion was performed in the HUK group, with once a day for 14 consecutive days. The rate of recurrent stroke and modified Rankin Scale (mRS) scores in two groups were analyzed 12 months after the treatment.ResultsNo difference was found in the age, gender, comorbidities, smoking history, and NIHSS scores between two groups before treatment (p > 0.05). 12 months after treatment, 10 patients in the HUK group (10.3%) and 26 patients in the control group (16.8%) got stroke recurrence at 12 months (p = 0.009). The mRS score of HUK group was significantly lower than that in the control group (2.3 ± 1.2 vs. 3.5 ± 1.4, p = 0.011).ConclusionHuman Urinary Kallidinogenase is able to reduce the risk of stroke recurrence and promote good recovery for AIS patients within 12 months.
Highlights
IntroductionA study in the United States showed that the incidence of stroke recurrence was 185,000 in 795,000 cases (23.3% per year; Go et al, 2013)
Nowadays, the risk of stroke recurrence is still high worldwide
This retrospective study showed that patients treated with Human Urinary Kallidinogenase (HUK) had a decreased risk for stroke recurrence within 1 year compared with controls
Summary
A study in the United States showed that the incidence of stroke recurrence was 185,000 in 795,000 cases (23.3% per year; Go et al, 2013). Another study obtained data from the Swedish Stroke Register between 1998 and 2009 reported that 11.3% of 196 765 patients with ischemic stroke had a recurrent ischemic stroke within 1 year (Bergström et al, 2017). Stroke Registry from 2007 to 2008 showed that the recurrence rate of patients with acute ischemic stroke (AIS) was nearly 20% at 12 months (Wang et al, 2013). HUK has been listed as a state category I new drug for the treatment of stroke patients by China’s State Food and Drug Administration. Many studies showed that HUK has therapeutic effect for AIS (Wu, Lyu, Zhong, Liu, & Liu, 2017).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
